RenovoRx, Inc.
RNXT· Nasdaq
Released Aug 13, 2026, after the close
10-Q filed Aug 13, 2026, 44 days after period end · 0001193125-26-349190
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $909.00K | $422.00K | — | — |
| Net Income | -$2.91M | -$2.90M | -$2.39M | -$2.33M |
| EPS Diluted |
RenovoRx, Inc. · CIK 1574094 · Engraved from SEC EDGAR
| -$0.06 |
| -$0.08 |
| -$0.10 |
| -$0.22 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.